openPR Logo
Press release

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)-Pipeline Review, H2 2017

11-02-2017 01:49 PM CET | Health & Medicine

Press release from: MarketResearchReports.biz

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen

"The Report Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

Summary

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) pipeline Target constitutes close to 10 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The latest report Plasminogen Activator Inhibitor 1-Pipeline Review, H2 2017, outlays comprehensive information on the Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

View Report @ https://www.marketresearchreports.biz/reports/1361352/plasminogen-activator-inhibitor-1-endothelial-plasminogen-activator-inhibitor-or-pai1-or-serpine1-pipeline-review-h2-2017-market-research-reports

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)-Plasminogen activator inhibitor-1 (PAI-1) also known as endothelial plasminogen activator inhibitor or is a protein that encodes by the SERPINE1 gene. Elevated PAI-1 is a risk factor for thrombosis and atherosclerosis. PAI-1 is mainly produced by the endothelium and also by other tissue types, such as adipose tissue. PAI-1 inhibits the serine proteases tPA and urokinase and hence inhibit the physiological process that degrades blood clots. PAI-1 inhibits the activity of matrix metalloproteinases (important role in invasion of malignant cells across the basal lamina). The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 1 and 1 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 6 molecules, respectively. Report covers products from therapy areas Cardiovascular, Genito Urinary System And Sex Hormones, Immunology, Metabolic Disorders, Oncology, Respiratory, Central Nervous System and Gastrointestinal which include indications Obesity, Pulmonary Fibrosis, Renal Failure, Thrombosis, Acute Ischemic Stroke, Ageing, Arterial Thrombosis, Bone Marrow Transplant Rejection, Diabetes, Emphysema, Focal Segmental Glomerulosclerosis (FSGS), Graft Versus Host Disease (GVHD), Hepatic Veno Occlusive Disease, Hypertension, Kidney Fibrosis, Liver Fibrosis, Metastatic Lung Cancer, Multiple Sclerosis, Ovarian Cancer, Stroke, Thromboembolism and Transplant Rejection.

Furthermore, this report also reviews key players involved in Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Get Sample Copy Of This Report @ https://www.marketresearchreports.biz/sample/sample/1361352

Scope

- The report provides a snapshot of the global therapeutic landscape for Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)
- The report reviews Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics

Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/1361352

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
Email: sales@marketresearchreports.biz

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)-Pipeline Review, H2 2017 here

News-ID: 799023 • Views: 134

More Releases from MarketResearchReports.biz

Hydro-flyers Market: Moving Towards a Brighter Future
A hydro-flyer is an adventure sporting device which uses the propulsion of water jet technology to create continuous flight movement, where the lift and movement are controlled by the flyer. Hydro-flyers sporting devices make use of the flow of water power to drive the flyer to reach soaring heights. The rise in water sporting facilities is one of the major factors that promote the growth and demand for hydro-flyers in
Outdoor Floodlights: Technology and Market Dynamics
Outdoor floodlights is a reliable, highly efficient, and economical solution for a wide range of outdoor applications. These lights are resistant to temperature fluctuations and they remain stable even in extreme climatic conditions. Unlike the traditional lights, floodlights remain stable and functional even in harsh climatic conditions. This makes them ideal for use in any climate and any outdoor application. Outdoor floodlights save a significant amount of energy and consume
Snow Helmets Market Future Prospects and Regional Outlook
Riders are riding faster and getting bolder day by day. Hence, safety equipment need to be updated as per the requirement and changing time. Earlier, helmets were primarily used by extreme skiers and racers. They were used only on slopes. However, later, the use of helmets was made compulsory. Earlier, bulky black helmets were used by riders, which are outdated at present. Currently, new stylish helmets that can match with
Predictions for 2019: Global Sparkling Water Dispensers Industry Is Set to Boom
Sparkling water dispensers are equipment used for dispensing carbonated water. These dispensers mix the still, filtered water with carbon dioxide before dispensing. Sparkling water dispensers are mostly used in households and commercial establishments such as amusement parks, hotels, restaurants, and sports arenas. A sparkling water dispenser has separate outlets for hot water and cold water. The hot water outlet does not require a separate filtration process. However, cold water is

All 5 Releases


More Releases for Plasminogen

Global Plasminogen Market Growth 2019-2024
Plasminogen, the proenzyme of the fibrinolytically active enzyme plasmin, is a single chain glycoprotein with a molecular weight of about 90,000-94,000 Da (2). Various isoelectric forms exist and can be separated by means of isoelectric focusing (IEF). The complete amino acid sequence contains 790 amino acids. Native plasminogen (glu-plasminogen) has a N-terminal glutamic acid group. Partial plasma proteolysis gives rise to a molecule with N-terminal lysine (lysplasminogen). Currently, the product has obtained
Global Plasminogen Market Analysis 2012-2017 and Forecast 2018-2023
Plasminogen, the proenzyme of the fibrinolytically active enzyme plasmin, is a single chain glycoprotein with a molecular weight of about 90,000-94,000 Da (2). Various isoelectric forms exist and can be separated by means of isoelectric focusing (IEF). The global Plasminogen market will reach xxx Million USD in 2018 and CAGR xx% 2018-2023. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast
Global Plasminogen Market 2019 - Kedrion, Prometic, Genentech (Roche)
This new report by Eon Market Research, titled “Global Plasminogen Market 2019 Research Report, 2015 – 2025” offers a comprehensive analysis of Plasminogen industry at a global as well as regional and country level. Key facts analyzed in this report include the Plasminogen market size by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025. This report primarily focuses on the study of the competitive
Tissue Plasminogen Activator Market Research Report 2017
Reports And Markets Publish a New Market Research Report On –"Tissue Plasminogen Activator Market Research Report 2017" Access Full Report With Table Of Contents @ https://www.reportsandmarkets.com/reports/global-tissue-plasminogen-activator-market-research-report-2017-1541236 In this report, the global Tissue Plasminogen Activator market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several
Global Tissue Plasminogen Activator Market Professional Survey Report 2017
The Global Tissue Plasminogen Activator Market Professional Survey Report 2017 is a professional and in-depth study on the current state of the Tissue Plasminogen Activator industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Tissue Plasminogen Activator market analysis is provided for the international market including development history, competitive landscape analysis, and major regions’ development status. Secondly, development policies and plans are discussed as well as
Global Plasminogen Activator Inhibitor Market 2017 - Bayer AG, SteadyMed, GlaxoS …
The Plasminogen Activator Inhibitor Market 2017 Research Report investigates a thorough and complete study on Plasminogen Activator Inhibitor industry volume, market Share, market Trends, Plasminogen Activator Inhibitor Growth aspects, wide range of applications, Utilization ratio, Supply and demand analysis, manufacturing capacity, Price durinf Forecast period from 2017 to 2022 The research report labeled Global Plasminogen Activator Inhibitor Market 2017 presents the penetrating study of Plasminogen Activator Inhibitor market globally, concentrating on